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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
in the world wide, with incidence of more than 30 per 1,00,000 population in India. It can 
arise anywhere in the upper aero digestive tract, particularly in the oral cavity, larynx, 
pharynx and salivary glands [Joshi P, 2014]. 
Different types of carcinomas can affect the oral cavity such as Squamous cell 
carcinoma, Verrucous carcinoma (VC), Adenocarcinomas, Spindle cell carcinoma, 
Lymphoepithelial carcinoma, etc. Among these, squamous cell carcinoma is the most 
frequently reported, accounting for more than 95% of cases [Choi S, 2008]. 
Early oral squamous cell carcinoma often presents as a white patch, red patch or a 
mixed red and white lesion. With time, superficial ulceration of the mucosal surface may 
develop. As the lesion grows, it may become an exophytic mass with a fungating or papillary 
surface [Neville, 2013]. 
Verrucous carcinoma represents about 3% to 4% of all oral carcinomas. Oral 
verrucous carcinoma is an uncommon tumor which presents as a tan/ white, warty growth 
with a broad base attachment. It was considered as a low-grade variant of oral squamous cell 
carcinoma. Lauren V. Ackerman in 1948 described it as a distinct variant of differentiated 
squamous cell carcinoma with low grade malignancy, which displays both exophytic and 
endophytic growth with a pebbly, micro nodular surface and tends to spread locally with no 
evidence of metastasis even in advanced cases. It has a much better prognosis than 
conventional oral squamous cell carcinoma [Shergill AK et al., 2015 and Yunus SM et al., 
2016]. 
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One of the characteristic clinical features of oral squamous cell carcinoma is its 
capacity to invade the adjacent tissues and metastasize in a locoregional manner. This 
involves disruption of normal cell to cell adhesion [Pyo et al., 2007]. 
The prevalence of oral cancer continuously increased and the poor survival has not 
been changed in recent 30 years, and the poor prognosis of OSCC is always correlated with 
metastasis. Therefore, it’s important to find a reliable biomarker for prediction of progression 
and overall survival and elucidation of the underlying molecular mechanisms are essential to 
understand the clinical behavior and facilitate the management of OSCC [Huang et al., 
2014]. 
The caveolins are invaginations in the plasma membrane 50-100 nanometers in 
diameter. Caveolins are found predominantly at the plasma membrane but also in the Golgi, 
the endoplasmic reticulum, in vesicles, and at cytosolic locations. The highest levels of 
caveolin-1 are found in terminally-differentiated cell types, such as adipocytes, endothelia, 
smooth muscle cells, and type I pneumocytes [Williams et al., 2004]. 
Caveolae are 50–100 nm flask-shaped invaginations of the plasma membrane 
enriched in cholesterol and glycosphingolipids. Caveolae can exist as individual 
invaginations or can be found in detached grape-like clusters and long tubular structures 
derived from the fusion of single caveolae. Caveolin-1 is a structural protein component of 
caveolae in most cell types [Kurzchalia et al.,1992]. 
Caveolae play a pivotal role in cholesterol transport, endocytosis, potocytosis, and 
signal transduction. The caveolae family has three proteins: Caveolin-1(Cav-1), Cav-2, and 
Cav-3. The oncogenic role of Cav-1in cancer has been widely investigated in multiple studies 
[Liu et al., 2015]. 
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caveolin-1 contains a so-called scaffolding domain that binds to and inhibits the 
activity of several signaling proteins in vitro and in situ [Torres et al., 2006]. 
Role of Cav-1 in development of several human cancers have been implicated in 
previous studies . The role of Cav-1 still remains controversial in OSCC. Two research 
groups found that an increased Cav-1 expression plays an important role in carcinogenesis 
and development of OSCC. In contrast, few studies disclosed that the inactivation of Cav-1 
by a mutation or by reduced expression might play a role in the pathogenesis of oral cancer, 
which indicated its biphasic role and value to explore Cav-1’s functions in OSCC [Xue et al., 
2010]. 
A search of the available literature revealed that no attempt has been made to identify 
the significance of Caveolin-1 in verrucous carcinoma (VC). The aim of the present work 
therefore is to study the patterns of expression of  Caveolin-1 in verrucous carcinoma (VC) 
and various grades of oral squamous cell carcinoma (OSCC) by immunohistochemistry 
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AIM OF THE STUDY 
 To evaluate immunohistochemically, the expression of Caveolin-1 in 
verrucous carcinoma (VC)  
 To evaluate immunohistochemically, the expression of Caveolin-1 in well 
differentiated oral squamous cell carcinoma(OSCC). 
 
OBJECTIVES OF THE STUDY 
 To compare the immunohistochemical expression pattern of  Caveolin-1 
in verrucous carcinoma and in well differentiated oral squamous cell 
carcinoma. 
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Oral cancer accounts for 4-5% of all cancers in the world. Oral squamous cell 
carcinoma (OSCC) accounts for 90% of all oral cancers. In spite of easy access to oral 
cavity for clinical examination, five years survival rate of oral squamous cell carcinoma 
patients varies from 40-50% and is usually diagnosed in advanced stages [Markopoulos, 
2012]. 
OSCC may appear in any location, although there are certain areas in which it is 
more commonly found. The most Common sites for OSCC are the tongue, lips and floor 
of the mouth and buccal mucosa. [Markopoulos, 2012] OSCCs lesions have a variable 
size and can range from a few millimeters to several centimeters in more advanced cases 
[Bagan J et al., 2010]. 
OSCC may take various clinical forms. It may resemble as leukoplakia, verrucous 
leukoplakia, or erythroplakia, any of which may eventually develop into a necrotic ulcer 
with irregular, raised indurated borders, or into a broad based exophytic mass with a 
surface texture which may be verrucous, pebbled or relatively smooth [Feller L, 2012]. 
OSCCs are classified histopathologically, according to the degree of 
keratinization, cellular and nuclear pleomorphism and mitotic activity. In well 
differentiated tumors (grade 1), the tumour cells resemble normal epithelial cells, 
arranged in an orderly stratification. Heavy keratinization can be found in pearl 
formations. In moderately differentiated tumors (grade 2), the cells are less stratified, less 
keratinized, distinct nuclear pleomorphism and mitotic activity, including abnormal 
mitoses. In poorly differentiated tumors (grade 3), predominately the cells are immature 
with numerous typical and atypical mitoses, and little or no keratinization. Well and 
moderately differentiated tumours can be grouped together as low grade and poorly 
differentiated and undifferentiated tumours as high grade [Woolgar JA, 2006 & Pereira 
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MC, 2007]. This histopathological grading is an important factor in determining the 
prognosis of Oral squamous cell carcinoma. The prognosis is best when the primary 
tumour is small, well differentiated and there is no evidence of regional lymph node 
involvement or distant metastasis [Feller L, 2012]. 
Verrucous carcinoma (VC) can occur in several locations in the head and neck 
region and in the genitalia. However, the oral cavity is the most common site. [Medina J 
E, 1984]. Its occurrence includes buccal mucosa, mandibular alveolar crest, gingiva and 
tongue. It is a slow growing tumor, which presents predominantly as an exophytic growth 
with a pebbly, micronodular surface. Histopathologically, VC presents with a 
hyperplastic epithelium with abundant keratin superficially projecting as exophytic 
church-spire keratosis and also showing parakeratin plugging, bulbous well oriented rete 
ridges, endophytic growth pattern with pushing borders, minimal or no pleomorphism of 
cells and no mitotic activity above the basal and suprabasal layers of the epithelium. It 
tends to spread locally with no evidence of metastasis even in advanced cases [Shergill et 
al., 2015]. 
There is an inadequate knowledge in relation to the development and progression 
of oral cancer. The development of cancer may also involve change in expression of 
various proteins. The study of proteins which change in oral cancer will provide valuable 
information and will help in the understanding of the disease. It also identifies the 
proteins which can be potentially utilized as markers for early cancer detection [Karsani 
SA, 2014]. 
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CAVEOLINS 
Caveolins are a family of proteins which are plasma membrane invaginations that 
generally form caveolae structures. Caveolae have one transmembrane and two 
cytoplasmic microdomains and are critical components for interactions between integrin 
receptors and intracellular signaling molecules. The main proteins required for caveolae 
formation are three caveolins: caveolin-1 (Cav-1), caveolin -2, and caveolin-3. 
[Ashkavandi et al, 2017]. Caveolins are found predominantly at the plasma membrane, 
however, their expression levels vary considerably between tissues. Caveolin-1 is widely 
expressed in human tissues. The highest levels of Cav-1 are found in the terminally 
differentiated cells, such as adipocyte, endothelia and smooth muscle cells, as well as 
type I pneumocytes. The localization and expression of Cav-2 is mapped to Cav-1 and is 
required for the proper membrane localization of Cav-2, whereas Cav-3 is expressed 
predominantly in the muscle cells, including the smooth, skeletal and cardiac myocyte 
cells. [Chen D, et al. 2014].  
Cav-1 is the major isoform and many researchers suggests that Cav-1 expression 
is related to malignant transformation, differentiation, angiogenesis, tumor stage and 
metastasis, chemotherapeutic response, and other clinical characteristics. It has been 
shown that the prognostic value of caveolin is strongly cancer- specific [Ashkavandi et 
al, 2017]. 
Caveolin-1, a protein of 21–24 kDa, was first described as the major substrate for 
tyrosine phophorylation when cells were transformed by the Rous sarcoma virus 
[Glenney and Soppet 1992]. Caveolin-1 acts as the driving force for caveolae formation 
and regulates the import and export of cellular cholesterol due to its ability to form homo-
oligomers and its interaction with cholesterol and glycosphingolipids [Razani et al. 
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2001]. Caveolin-1 also plays a key role in membrane traffic by attracting proteins to 
caveolae as a molecular motor that powers membrane invagination and budding [Liu et 
al. 2002]. Through its special motif, the scaffolding domain, caveolin-1 interacts with 
lipid modified signaling molecules such as G-protein alpha subunits, H-ras, Src-family 
tyrosine kinases, endothelial nitric oxide synthase, epidermal growth factor receptor 
(EGFR), mitogen-activated protein kinase (MAPK), transforming growth factor-
β/SMAD, and the Wnt/ β-catenin/lef-1 pathway [Li et al. 1996; Cardena et al. 1996; 
Mineo et al. 1996; Galbiati et al. 2000].  
 
Caveolae signaling hypothesis:  
The hypothesis states that caveolar localization of various inactive signaling 
molecules provides a compartmental basis for their subsequent regulated activation, and 
explains „„crosstalk‟‟ between different signaling pathways. 
Cav1 has been reported as the linkage between caveolae and the cytoskeleton. 
Caveolae are found to align with actin filaments via the interactions of Cav1 with myosin 
sub-fragment I and filamin. Apart from localizing in caveolae, Cav1 is also found in the 
nucleus, cytoplasm, extracellular milieu, and focal adhesions. Cav1 proteins are involved 
in cell signaling and interactions with the intracellular cytoskeleton complex, which in 
turn regulate cell adhesion and locomotion. Phosphorylation of Cav1 on Tyr14 localizes 
Cav1 to focal adhesions and has been implicated in cell polarization, migration, and focal 
adhesion dynamics. Interactions of Cav1 with c-Fyn and a subset of β1 integrins at focal 
adhesions, which subsequently led to fibronectin adhesion and Ras–MAPK signalling 
cascade activation. [Tse et al, 2012] 
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The structure of Cav-1 
Cav-1 is a 21–24 kDa integral membrane protein, consisting of two isoforms,     
α-isoform with a slower migration (containing residues 1–178) and β-isoform with a 
faster migration (containing residues 32–178).34,35 Previous study also demonstrated 
that both isoforms contain the oligomerization (residues 61–101).36 It was reported that 
Cav-1 has a central hydrophobic domain (residues 102–134), which are considered to 
form an unusual hairpin loop structure in the membrane, thus leading to both the amino-
terminal domain (residues 1–101) and the carboxyl-terminal domain (residues 135–178) 
of Cav-1 face with the cytoplasm. The residues between 80 and 101 have termed the 
caveolin scaffolding domain (CSD).38 Numerous signal molecules can interact with Cav-
1 via the CSD, including Src family tyrosine kinases, Rho-GTPases, growth factor 
receptors, endothelial nitric oxide synthase (eNOS), G-proteins and G-protein-coupled 
receptors. However, Cav-1 can negatively or positively regulate these signaling 
molecules, thus playing a vital role in cancer progression. [Fu et al. 2017] 
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Detailed organization of lipid rafts and caveolae membranes. A, lipid rafts: the liquid-
ordered phase is dramatically enriched in cholesterol (shown in yellow) and exoplasmic 
oriented sphingolipids (sphingomyelin and glycosphingolipids) (shown in orange). In 
contrast, the liquid-disordered phase is composed essentially of phospholipids, such as 
phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (shown in 
green). B, caveolae: the liquid-ordered and liquid-disordered phases are illustrated as in 
panel A. Upon integration of the caveolin-1 protein, liquid-ordered domains form small 
flask-shaped invaginations called caveolae. Caveolin-1 monomers assemble into discrete 
homo-oligomers (shown as dimers for simplicity) containing _14 to 16 individual 
caveolin molecules. Adjacent homo-oligomers are thought to pack side-by-side within 
caveolae membrane thereby providing the structural meshwork for caveolae invagination. 
Caveolin-1 oligomers are red and the caveolin-1 oligomerization domain is shown in 
blue. [Razani B, et al. 2002] 
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The current view of caveolin-1 membrane topology. Caveolin-1 exists as either a homo-oligomer of _14 to 
16 monomers (shown as a dimer for simplicity) or as a hetero-oligomer with caveolin-2 (not shown). Via 
its hydrophobic trans-membrane (TM) domain (red), Cav-1 is believed to penetrate the membrane. The 
protein is also bound to membranes through tight association between the N-MAD and C-MAD (shown in 
lavender and green, respectively). Homo-oligomerization is mediated by a 40-amino acid stretch (residues 
61–101; which incidentally encompasses N-MAD) known as the oligomerization domain (OD) (hashed 
brown). Adjacent oligomers interact via the terminal domain (TD) (purple). Sites of palmitoylation 
(Cys133, -143, and -156) are shown in blue. [Razani B, et al. 2002] 
 
THE ROLE OF CAV-1 IN INVASION, MIGRATION AND 
METASTASIS 
Cav-1 and Rho-GTPases 
There is increasing evidence that Rho-GTPases are likely to play a role in tumor 
metastasis and invasion. Previous studies also have demonstrated the pivotal role of Cav-
1 in regulating the activity of Rho-GTPases in various cancers. The cooperation between 
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Cav-1 and Rho-GTPases promotes tumor metastasis, which mainly depend on the 
elevated expression of α5-integrin and the enhanced activation of Src, Ras and Erk. 
Moreover, an increased expression of Cav-1 can promote the activation of AKT1, leading 
to the increased phosphorylation of RhoC GTPase. As a consequence, the invasion 
capacity of breast cancer cells is significantly elevated. These phenomena are not in 
accordance with the study reported by Lin et al who indicated that Cav-1 expression 
inhibits RhoC GTPase activation and subsequently activates the p38 mitogen-activated 
protein kinase (MAPK) pathway, thus restricting migration and invasion of primary 
pancreatic cancer cells. [Fu et al. 2017] 
Cav-1 and epithelial-to-mesenchymal transition (EMT) 
Evidences suggested that Cav-1 can mediate the invasion and metastasis of cancer 
and often accompanied by the EMT. Some studies are referred to clarify the effect of 
Cav-1 in regulating EMT in cancers. Cav-1 can promote bladder cancer metastasis via 
inducing EMT by activating the phosphatidylinositol 3-kinase (PI3K)/AKT signaling 
pathway, thus upregulating Slug expression. In addition, overexpression of Cav-1 
significantly increases vimentin expression, but decreases E-cadherin expression, leading 
to EMT, which may explain the motility and invasion ability in hepatocellular carcinoma 
(HCC). Whereas the reduced levels of Cav-1 function by hypoxia increases epidermal 
growth factor receptor (EGFR) activation, leading to the activation of signal transducer 
and activator of transcription 3 (STAT3), resulting in the downregulation of E-cadherin 
and upregulation of mesenchymal markers (Slug, a-SMA, N-cadherin and vimentin), 
suggesting that Cav-1 can mediate the EMT and promote the invasive potency in gastric 
cancer (GC).46 Furthermore, the decreased expression of Cav-1 by EGF leads to the loss 
of E-cadherin, disruption of cell–cell contacts and enhances glycogen synthase kinase 3 
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(GSK-3)-independent-catenin-T-cell factor (TCF)/lymphoid enhancer factor 1 (LEF-1) 
transactivation and increased transcriptional activity of β-catenin, resulting in enhancing 
cancer cells invasion and metastasis.[Fu et al. 2017] 
 
 
 
 
Cav-1 plays an important role in tumor migration, invasion and metastasis by regulating 
the activity of Rho GTPases, EMT and MMPs. . [Fu et al. 2017]
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Cav-1 and matrix metalloproteinase (MMP) 
MMPs are a family of zinc-containing proteolytic enzymes that degrade various 
components of ECM. Numerous studies indicated that high expression levels of certain 
MMPs are related to the cancer invasion and metastasis capacity. Many researches have 
studied the relationship between Cav-1 and MMP, but came out with different results. It 
has been demonstrated that membrane type 1 (MT1)-MMP colocalizes with caveolae and 
Cav-1. Cav-1 may function as a negative regulator by inhibiting MT4-MMP expression, 
which is associated with the metastasis in colon cancer. Furthermore, Cav-1 overex-
pression can reduce the metastasis and invasion capacity of metastatic mammary tumor 
cells by inhibiting the activity of MMP-2 and MMP-9. In contrast, the motility and 
invasion-promoting effect of Cav-1 overexpression in HCC may be partly through 
increasing secreted MMP-2 and expression levels of MMP-9 and MT1-MMP, as well as 
inducing an EMT-like phenotype. Consistent with the above results, Cav-1 might 
promote the invasion and metastasis potential via decreasing of E-cadherin protein 
expression and activate the enzyme activity of MMP3 as in human small cell lung cancer. 
[Fu et al. 2017] 
The role of Cav-1 in cell cycle 
Cav-1 mediates the development of tumor by inversely regulating the cell cycle 
progression. The control of the cell cycle involved in two major 
“checkpoints/transitions”, more specifically, the G1→S transition and the G2→M 
transition. Besides, cyclins/cyclin-dependent kinases (CDKs) and CDK inhibitors are the 
key regulatory factors of the two transitions. Cav-1 may negatively regulate the 
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transcriptional activity of two major components (cyclinD1 and CDC25A) of the cell 
cycle regulatory apparatus that governs DNA synthesis and cell transformation. 
Moreover, the decreased expression of Cav-1 by interfering RNA significantly reduces 
the expression of phospho-AKT, cyclinD1 and CDK4, downstream transducers 
phosphorylated ERK and STAT3, thus leading to the inhibition of the metastatic lung 
cancer cells proliferation. In addition, Cav-1 expression negatively regulates cell cycle 
progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent pathway. [Fu 
et al. 2017] 
The role of Cav-1 in apoptosis 
Apoptosis is an active and physiological process of cell death, and the imbalance 
is one of the important factors for the formation of malignant tumor. Yet, the role of Cav-
1 on apoptosis regulation fails to reach a consensus. Many previous studies have 
demonstrated that Cav-1 is capable of promoting cell apoptosis. The study of HEK293T 
and ZR75 cell lines indicated that antiproliferative and proapoptotic properties of Cav-1 
may be attributed to reducing survivin (inhibitor of apoptosis protein) expression via a 
mechanism involving diminished β-catenin-TCF/LEF-dependent transcription. Moreover, 
overexpression of Cav-1 exhibits slower growth and promotes cell apoptosis in human 
cancer by inhibiting the activities of EGFR-MAPK signaling pathway. However, Cav-1 
can inhibit apoptosis through various signal pathways. It has been shown that the absence 
of Cav-1 significantly reduces the activation of the AKT pathway mediated by 
Transforming growth factor beta (TGF-β), thus contributing to the increased expression 
of proapoptotic proteins BIM. Besides, a significant decrease of antiapoptotic protein B-
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cell lymphoma (BCL)-2 and BCL-xl expression is observed, suggesting the elevation of 
the hepatocyte apoptosis.61 Furthermore, the expression of Cav-1 in human breast cancer 
cells is able to inhibit anoikis ( a type of programmed cell death)s and enhances matrix-
independent survival by a mechanism, which involves upregulation of insulin-like growth 
factor (IGF)-insulin receptor (IR) expression and IGF-I-induced PI3K/AKT signaling 
pathway. From another point of view, Cav-1 could maintain phosphorylated AKT 
through scaffolding binding site interaction and inhibition of serine/threonine protein 
phosphatases (PP1 and PP2A), and that elevated AKT activities are largely responsible 
for Cav-1-mediated survival in prostate carcinoma cells. Based on the research of the 
breast cancer cell line Hs578T, the results suggested that Cav-1 overexpression 
significantly reduces staurosporine-induced apoptosis through inhibition of neutral 
sphingomyelinase, decrease of ceramide, which can inhibit PI3K/AKT pathway that 
mediates cell apoptosis. Taken together, the effect of Cav-1 on cell apoptosis is an 
extremely complex process[Fu et al. 2017]. 
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The role of Cav-1 in apoptosis fails to reach a consensus. 
Notes: Increased apoptosis: Cav-1 overexpression can promote cell apoptosis by downregulation of EGFR-
MAPK signal pathway6,9 or β-catenin-TCF/LEF-dependent transcription60 and its downstream signal 
molecules survivin.60 However, Cav-1 knockdown also can inhibit the expression of antiapoptotic proteins 
BCL-2 and BCL-xl. Simultaneously, Cav-1 can negatively regulate the activity of AKT, leading to the 
upregulation of BIM.61 Decreased apoptosis: Cav-1 inhibits anoikis by upregulation of IGF-IR expression 
and IGF-I-induced signaling via the PI3K/AKT pathway.62 Moreover, the elevated expression of Cav-1 
can maintain phosphorylated AKT through scaffolding binding site interaction and inhibition of PP1 and 
PP2A.63 Furthermore, Cav-1 overexpression also significantly reduces staurosporine-induced apoptosis by 
downregulation of the ceramide via inhibiting the activity of neutral sphingomyelinase, the decreased 
ceramide inhibits P13K/AKT pathway-induced cell apoptosis.64 The “+” represents the promotion and “-” 
represents the inhibition. 
Abbreviations: BCL, B-cell lymphoma; Cav-1, caveolin-1; EGFR, epidermal growth factor receptor; 
EMT, epithelial-to-mesenchymal transition; GSK, glycogen synthase kinase; IGF, insulin-like growth 
factor; IR, insulin  receptor; LEF, lymphoid enhancer factor; MAPKs, mitogen-activated protein kinases; 
PI3K, phosphatidylinositol 3-kinase; PP, protein phosphatase; TCF, T-cell factor. [Fu et al. 2017] 
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Several research groups have implied that caveolin-1 might fulfill a tumor-
suppressor role [Engelman et al. 1998; Bender et al. 2001; Wiechen et al. 2001; Cui et 
al. 2001; Racine et al. 1999]; however, others have reported a positive association of 
caveolin-1 with tumorigenesis and progression, thereby suggesting a tumor-promoting 
function [Kato et al. 2002; Yang et al. 1998; Yang et al. 1999; Ito et al. 2002, Ho et al. 
2002]. These conflicting results refer to the complex physiological functions of caveolin-
1 and its contribution to carcinogenesis.[Juhasz M et al, 2003] 
 
Mechanism of oncogenic or tumor suppressor function of caveolin-1 
Cav-1 has a tumor suppressor gene in ameloblastoma, ovarian carcinoma and 
different sarcomas [Jaspeado M et al.2011; Xu J, et al.2014; Ashkavandi et al.2015].  
The diverse roles of Cav-1 in different types of cancers could be probably due to 
both differential activation of different domains of Cav-1 and interaction of diverse 
molecules with Cav-1. It has been suggested that caveolin scaffolding domain in Cav-1 
confers a tumor suppressor activity, while tye-14 phosphorylation of Cav-1 is involved in 
cell growth stimulation. Thus, variation in Cav-1 function in carcinogenesis could be due 
to distinct genetic defects that verifies the capacity for differential Cav-1 expression in 
particular tumor types [Xue J et al. 2010] 
Cav-1 has been suggested to function both as a tumor suppressor or as an 
oncogene, depending on the tumor type and/or tumor stage by following mechanisms.  
1) Tyrosine phosphorylation; 2) Serine phosphorylation; and 3)Dominant-negative 
point mutation, P132L.   
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Tyrosine Phosphorylation: 
The dually contrasting roles for Cav-1 in tumor progression may be partly 
explained by the observation that Cav-1 has several peptide domains with opposing 
functions. A molecular 
dissection of the Cav-1 protein has revealed distinct regions that may counteract the 
effects of the growth-inhibitory caveolin-scaffolding domain(CSD). Functionally, 
tyrosine 14-phosphorylated Cav-1 binds Growth factor receptor bound protein (Grb7) and 
enhances both anchorage-independent growth  and EGF-stimulated cell migration. Thus 
tyrosine phosphorylated Cav-1 may function like a growth factor receptor that recruits 
Src Homology 2(SH2) domain-containing proteins to the plasma membrane. 
Serine Phosphorylation : 
A second region of Cav-1 also appears to have growth stimulatory properties. 
Serine phosphorylation of Cav-1 changes its topology, thereby converting Cav-1 from an 
integral membrane protein to a secreted protein product. 
Dominant-Negative Point Mutations: 
The identification of Cav-1(P132L) mutations in up to 16% of human breast 
cancers provides a third distinct mechanism to inactivate the tumor suppressor function of 
caveolin-1. This mutation drives cellular transformation in NIH 3T3 cells. Briefly, NIH 
3T3 cells expressing Cav-1 (P132L) show augmented growth in soft agar, as well as 
increased invasiveness, and increased chemotaxis. [ William TM et al. 2005] 
Ectopic Caveolin-1 inhibits Firoblast Growth Factor 2 (FGF2) as well as 
epidermal growth factor (EGF) signaling in densely growing cells. Caveolin-1 plays an 
important role in contact inhibition, moving to cell-cell contacts. The bimodal function of 
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Caveolin-1 might be regulated by differential localization of Caveolin-1. In sparsely 
growing cells, Caveolin-1 localized in caveolae exerts a stimulatory function on Receptor 
Tyrosine Kinase (RTK signaling). At cell confluency, the distribution of Caveolin-1 
changes from a uniform punctate distribution over the entire cell surface and becomes 
localized primarily to areas of cell-cell contacts. There it exerts its inhibitory function on 
different signaling molecules to regulate cell contact inhibition. However, the effect of 
Caveolin-1 on RTK signaling does not differ between FGF2- and EGF-mediated p42/44 
ERK activation. [Basel et al. 2007] 
Caveolin-1 and oxidative stress: 
The cumulative production of reactive species, particularly reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), through either endogenous or 
exogenous insults is termed oxidative stress. Oxidative stress has been reported to be 
implicated in the etiology and progression of multiple human diseases, such as 
neurodegenerative disease, inflammatory disease, cardiovascular disease, allergies, 
immune system dysfunctions, diabetes, and aging as well as cancer. Reactive species play 
an important role in cancer etiology. [Wang et al. 2017] 
Caveolin-1 has been shown to interact with numerous oxidative enzymes and 
could therefore be involved in the regulation of oxidative stress-induced pathways. In a 
study, H2O2 treatment decreased caveolin-1 expression and suggest that the protein is 
directly, but most remarkably, very quickly targeted by oxidative stress in proliferating 
mouse myoblasts.[Mougeolle et al. 2015] 
Nitric oxide (NO) is enzymatically generated from the conversion of L-arginine 
and oxygen through nitric oxide synthase (NOS) including the constitutive neuronal NOS 
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(nNOS), endothelial NOS (eNOS), and the inducible form of NOS (iNOS). In a study in 
ischemic brain, they found that that NO can down-regulate the expression of caveolin-1. 
[Shen et al. 2006] 
A key regulator of eNOS function is caveolin-1 which is expressed in aortic valve 
endothelial cells.  Caveolin-1 upregulation in the presence of lipids inactivates eNOS 
enzymatic function and further promotes oxidative stress. Experiments were performed to 
localize the expression of Caveolin-1 and eNOS in the aortic valve endothelial cell 
caveolae. [Rajamannan. 2013]. 
Modulation of protein palmitoylation by oxidative stress suggests a cellular 
mechanism by which stress might influence caveolin-1-dependent cell activities such as 
the concentration of signalling proteins and cholesterol trafficking. Oxidative stress 
decreases the trafficking of newly synthesized caveolin-1 to lipid rafts and that this effect 
is associated with a decreased rate of caveolin-1 palmitoylation. [Parat et al. 2003] 
Compared with normal cells, cancer cells usually demonstrate aberrations in 
oxidative metabolism and signaling pathways, characterized by increased levels of 
reactive species. Reactive species overproduction could induce tumorigenesis and 
progression possibly by modulating the expression, degradation, posttranslational 
modification (including tyrosine phosphorylation and palmitoylation and subcellular 
localization) of Caveolin-1. Human Caveolin-1 gene is localized to a suspected tumor 
suppressor locus (7q31.1), which is a fragile genomic region and often deleted in cancers, 
suggesting that Cav-1 is possibly a tumor suppressor. Meanwhile, Cav-1 mainly acts as a 
tumor suppressor during cancer initiation and development and also has a feedback 
regulation effect on oxidative stress. Particularly, Cav-1 seems to act as a tumor 
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suppressor at early stages of cancer progression but as an oncoprotein in advanced-stage 
cancer. [Wang et  al., 2017] 
 
EXPRESSION OF CAVEOLIN -1 IN CARCINOMAS OF VARIOUS 
REGION 
Some authors reported increased expression of Cav-1 in other malignancies such 
as melanoma, esophageal squamous cell carcinoma, pancreatic ductal adenocarcinoma, 
adenocarcinoma of the colon and lung adenocarcinoma [González L et al. 2013; Tanase 
CP et al.2009; Jia Y et al. 2014; Basu Roy UK et al.2013; Luan TY et al.2015] 
Downregulation appears more frequent in ovarian, colon cancer and mesenchymal 
sarcomas. On the contrary, upregulation is associated with lung, bladder, oesophageal , 
thyroid (papillary subtype) and prostate carcinomas. Owing to the pivotal roles played by 
caveolin-1 in signalling cascades, it is perhaps not surprising that overexpression has 
been reported to play a role in invasion, metastasis and resistance to therapy. [Patani N et 
al, 2012] 
Caveolin-1 expression in breast carcinoma 
Several independent groups has identified Cav-1 as a stromal biomarker, which is 
predictive of poor prognosis in breast cancer [Simpkins S A et al. 2012] 
In normal breast, CAV1 was expressed in myoepithelial cells, endothelial cells, 
and a subset of fibroblasts. Luminal epithelial cells showed negligible staining. The 
distribution and significance of caveolin1 (CAV1) expression in different breast cell 
types and role in breast carcinogenesis remain poorly understood as this protein possess 
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both tumor-suppressive and oncogenic roles. The CAV1 expression was 
immunohistochemically analyzed in benign lesions, breast cancer precursors, and 
metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from 
patients treated with surgery followed by anthracyclinebased chemotherapy. CAV1was 
expressed in 90% of 39 metaplastic breast carcinomas and in 9.4% of 245 invasive breast 
cancers. In the later cohort, CAV1expression was significantly associated with „basal-
like‟ immunophenotype and with shorter disease-free and overall survival on univariate 
analysis. CAV1 gene amplification was found in13% of cases with strong 
CAV1expression. The concurrent CAV1amplification and overexpression call into 
question its tumor suppressive effects in basal-like breast carcinomas [Savage k et al. 
2007]. 
The lower expression of stromal caveolin-1 is significantly associated with 
advanced tumour and nodal stage, lymphovascular invasion, metastasis, early recurrence, 
tamoxifen resistance and reduced median progression-free survival. The role of CAV-1 in 
tumour biology appears to be multidimensional [Patani N et al. 2012] 
Simpkins S A et al in 2012 assessed Cav-1 stromal expression  in 358 breast 
cancers and found that loss of Cav-1 expression in breast stroma was significantly 
associated with decreased breast cancer-specific and disease-free survival . Loss of 
expression of Cav-1 in breast CAFs was associated with increased tumour progression, 
local metastases, and oestrogen receptor negativity, all features related with poor 
outcome. Cav-1 loss in CAFs increases the aggressiveness of breast cancer cells. Absence 
of stromal Cav-1 has also been shown to be predictive of poor outcome in relation to 
specific breast cancer types. Cav-1 status could also be used to distinguish patients at 
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high and low risk of recurrence and breast cancer-related death. This information could 
potentially be used to inform treatment schedules; for example, chemotherapy for those 
with Cav-1-deficient stroma to prevent the increased risk of recurrence. 
Caveolin-1 expression in gastrointestinal carcinoma 
 Juhasz et al in 2003  studied the expression of caveolin-1 both in mRNA and 
protein level. Caveolin-1 mRNA expression was found to be down-regulated in gastric 
cancer as compared with that of the normal gastric mucosa. Caveolin-1 immunoreactivity 
was also markedly reduced in gastric cancer specimens in contrast to normal gastric 
epithelium. In the non-epithelial cell compartment of gastric cancer, caveolin-1 
expression was more intense in well-differentiated tumors than in undifferentiated and 
metastatic gastric cancers. Studies on the expression of caveolin-1 in gastrointestinal 
cancers showed that caveolin-1 is overexpressed in contrast to normal mucosa and was 
found to be a negative prognostic factor. 
Caveolin-1 expression in hepatocellular carcinoma 
Tse et al in 2012 investigated Cav1 expression in a panel of human HCC cell 
lines using western blotting analysis and quantitative RT-PCR and human tissues by 
immunohistochemistry. IHC was performed in 106 paired non-tumourous and tumourous 
liver tissues and 31 sets of samples comprising non-tumourous livers, primary HCCs, and 
extrahepatic metastatic tumours from the same patients. Cav1 was not detected in non-
tumourous liver but was exclusively expressed in tumourous liver. Dramatic expression 
of Cav1 was found in metastatic HCC cell lines and tumours, indicating a progressive 
increase of Cav1 expression along disease progression. Cav1 overexpression was 
significantly correlated with venous invasion. 
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Caveolin-1 expression in carcinoma of lung 
Seong-Ho Yoo et al in 2003 evaluated the IHC expression of caveolin-1, 107 
cases of pulmonary squamous cell carcinomas  and found Caveolin-1 expression in 34 
cases (31.7%) among 107 cases. The patients with caveolin-1 expression in pulmonary 
squamous cell carcinomas showed a poorer prognosis than those in caveolin-1-negative 
group. the expression level of caveolin-1 may be a candidate factor for predicting 
prognosis in patients with pulmonary squamous cell carcinoma.  
Kato T et al in 2004 assessed lung cancer specimens for caveolin-1 expression 
immunohistochemistry. A majority of the cell types in the lung and the bronchial 
epithelium normally exhibited positive staining for caveolin-1. In lung carcinoma tissue, 
the function of caveolin-1 may be tissue-dependent. In lung adenocarcinoma, the 
caveolin-1 serves as a tumor suppressor, with the loss of caveolin-1 regulation resulting 
in tumor extension and the lack of differentiation. In lung SCC, however, caveolin-1 
overexpression may correlate with tumor extension. 
Caveolin-1 was up-regulated in different drug-resistant cancer cell lines and was 
suggested to confer drug resistance by different mechanisms. IHC was performed in 73 
non-small cell lung cancer (NSCLC) patients, tumour specimens available before 
treatment were assessed. Immunoreactivity of caveolin-1 was correlated with the 
response to chemotherapy, the clinicopathologic features, and the progression-free 
survival (PFS) and overall survival (OS) of all patients. Patients with caveolin-1 
expression had a significantly lower response rate and a poor PFS and OS than those 
without caveolin-1 expression. Caveolin-1 expression significantly correlated with drug 
                                                                        REVIEW OF LITERATURE 
 
26 
 
resistance and a poor prognosis in advanced non-small cell lung cancer patients treated 
with gemcitabine-based chemotherapy  [Chao-Chi Ho et al. 2008] 
Caveolin-1 expression in ovarian carcinoma 
Davidson B et al in 2001 analyzed the correlation among the expression of 
caveolin-1and disease outcome in advanced-stage ovarian carcinomas. Sections from 76 
primary ovarian carcinomas and metastatic lesions from 45 patients diagnosed with 
advanced-stage ovarian carcinoma and twenty nonneoplastic fallopian tubes and ovaries 
were evaluated for caveolin-1 expression using immunohistochemistry. Caveolin-1 
expression was localized to the cell membrane in 32% specimens and cytoplasm in 68% 
specimens. Both patterns were detected in metastases and combined membrane and 
cytoplasmic immunoreactivity was seen in 85% nonneoplastic lesions. The reduced 
expression level in carcinomas compared to nonneoplastic epithelium may point to a role 
for caveolin-1 as a tumor suppressor gene. 
Caveolin-1 expression in pancreatic carcinoma 
Suzuoki et al in 2002 investigated the relationship between caveolin-1 IHC 
expression and the clinicopathologic variables and clinical outcome in 79 patients with 
pancreatic adenocarcinoma undergoing surgical resection. Positive caveolin-1 
immunostaining was detected in 32 cases, while non neoplastic ductal epithelium showed 
little or no staining. Positive caveolin-1 expression was correlated with tumour diameter, 
histopathologic grade and poor prognosis. Upon multivariate analysis, positive caveolin-1 
expression was shown to be an independent negative predictor for survival and suggests 
that caveolin-1 overexpression is associated with tumour progression, indicating a poor 
prognosis. 
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Tanase C P et al in 2009 examined the expression of Cav-1 in 34 human 
pancreatic ductal adenocarcinoma (PDAC) tissue samples and the associated peritumoral 
tissues by immunohistochemistry and western blot and found increased expression of 
Cav-1 in PDAC, when compared to either peritumoral areas or normal pancreata. 
Overexpression of Cav-1 is associated with tumor diameter, grade and stage.  Poorer 
prognosis could be associated with Cav-1 increased expression. These findings suggest 
that Cav-1 is as a good candidate marker for PDAC progression.Therefore, Cav-1 might 
be used as a novel biomarker for pancreatic cancer aggressiveness in a panel of 
biomarkers. 
Caveolin-1 expression in carcinoma of thyroid 
Ito Y et al in 2002 investigated caveolin-1 IHC expression in thyroid neoplasms. 
Normal follicular cells did not express caveolin-1. In papillary carcinoma, caveolin-1 
expression was observed in high incidence. In undifferentiated (anaplastic) carcinoma, its 
incidence was significantly reduced. On the other hand, all cases of follicular carcinoma 
and adenoma were classified as negative for caveolin-1. These results suggest that 
caveolin-1 may play a role predominantly in the early phase of papillary carcinoma, 
whereas it has little influence on follicular tumours. 
Caveolin-1 expression in prostate carcinoma  
Yang et al 1999 analyzed the prognostic value of cav-1 for progression of 
clinically confined human prostate cancer. Immunohistochemical staining with a 
caveolin-1 was performed on 189 radical prostatectomy specimens. Caveolin-1 
immunoreactivity was evaluated in association with patients‟ age, race, preoperative 
prostate-specific antigen, clinical stage, and pathological features including Gleason 
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score, extraprostatic extension, status of surgical margins, and time to disease progression 
after surgery. Multivariate analyses that included caveolin-1 and other prognostic 
pathological markers identified positive caveolin-1 immunostaining as an independent 
predictor for time to disease progression. Thus, authors establishes caveolin-1 as a novel 
prognostic marker for clinically confined human prostate cancer. 
Satoh T et al in 2003 performed immunohistochemical staining with a caveolin-1 
on 152 radical prostatectomy specimens and found a higher incidence of cav-1 expression 
in patients with poorly differentiated tumors and confirm that positive caveolin-1 
expression is associated with clinical markers of disease progression and is predictive of 
poor clinical outcome. 
Ayala G et al, in 2013 studied the levels of caveolin-1 (Cav-1) in tumour 
epithelial cells increase during prostate cancer progression. In a large cohort of 724 
prostate cancers, authors observed significantly decreased levels of stromal Cav-1 in 
concordance with increased Gleason score (p = 0.012). Importantly, reduced expression 
of Cav-1 in the stroma correlated with reduced relapse-free survival (p = 0.009), 
suggesting a role for stromal Cav-1 in inhibiting advanced disease. 
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TABLE-1: Summary of cav-1 expression in carcinomas of various organs [Fu et al. 2017] 
Organ Tumor Stromal 
 
Function 
 
Prognosis 
 
Function 
 
Prognosis 
 
Thyroid 
 
The level of Cav-1 
depends on the different 
subunits in thyroid cancer, 
whereas the results fail to 
reach an agreement 
   
Esophagus 
 
Cav-1 plays a negative 
role in the pathogenesis of 
BAC. 
 
The elevated 
expression of Cav-1 
in a small subgroup 
of BAC patients 
was correlated with 
poor survival 
prognosis 
  
Lung 
 
Cav-1 serves as a tumor 
inhibitor in lung ADs, 
whereas the tumor-
promoting function also 
has been observed. 
 
The higher 
expression Cav-1 
correlated with 
poorer survival in 
lung ADs patients. 
 
Cav-1 expression in 
CAFs is closely 
related with T 
stage, lymphatic 
permeation, 
vascular invasion 
and pleural 
invasion. 
Cav-1 
overexpression in 
CAFs predicts a 
poor outcome, but it 
cannot serve as an 
independent 
prognostic factor 
Liver 
 
The elevated Cav-1 
expression contributes to 
HCC progression and 
metastasis via inhibiting 
autophagy, inducing EMT 
or triggering c-Met signal 
transduction. 
Cav-1 
overexpression 
predicts a poor 
prognosis in HCC 
 
  
  Stomach 
 
Cav-1 can suppress gastric 
cancer tumorigenesis. The 
opposite results also have 
been observed 
 
Cav-1 is associated 
with poor prognosis, 
good prognosis or 
no prognosis 
remains 
controversial 
Loss of stromal 
Cav-1 can promote 
GC development 
 
Loss of stromal 
Cav-1 can predict 
the poor prognosis 
in GC 
 
  Pancreas 
 
Cav-1 acts as tumor 
inhibitor or tumor 
promotor, even with the 
both in pancreatic AD still 
remains controversial 
Cav-1 has been 
regarded as an 
independent 
unfavorable 
prognostic factor in 
pancreatic ductal 
AD 
The stromal Cav-1 
serves as a tumor 
suppressor in 
pancreatic cancer 
 
Loss of stromal 
Cav-1 in pancreatic 
cancer can be a 
strong poor 
prognosis biomarker 
 
  Colon 
 
The oncogenic function of 
Cav-1 was found in colon 
AD, whereas Cav-1 may 
play a tumor-inhibiting 
role during the early 
stages. 
   
Kidney 
 
Cav-1 can promote the 
progression and metastasis 
of renal cell carcinoma. 
Cav-1 may be 
capable of 
predicting a worse 
prognosis 
  
Prostate 
 
The tumorigenic function The increased The stromal Cav-1 Loss of stromal 
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of Cav-1 has been found 
in prostate cancer. 
expression of Cav-1 
is associated with 
poor prognosis. 
plays a tumor-
inhibiting role in 
the progression of 
prostate cancer. 
Cav-1 in prostate 
cancer heralds a 
worse prognosis 
 
Abbreviations: ADs, adenocarcinomas; CAFs, cancer-associated fibroblasts; Cav-1, caveolin-1; EMT, 
epithelial-to-mesenchymal transition; GC, gastric cancer; HCC, hepatocellular carcinoma 
  
Table - 2 : The role of Cav-1 in different histological types of carcinoma of the 
same organ [Fu et al. 2017] 
ORGAN FUNCTION 
Esophagus  
Cav-1 overexpression is associated with lymph node metastasis, pathologic 
stage and poor prognosis in ESCC, which have reported by many studies. 
However, Jin et al showed that both Cav-1 methylation frequency and NMV 
were significantly higher in EAC and ESCC than in corresponding normal 
esophagus. The loss of Cav-1 may contribute to the progression to Barrett 
adenocarcinoma of the esophagus. Taken together, Cav-1 plays a tumor-
inhibiting role in EAC, whereas Cav-1 plays a tumor-promoting role of in 
ESCC 
 
Lung  
The significant difference of Cav-1 expression is found between lung SCC and 
lung ADs. More specifically, the expression of Cav-1 is usually low or lost in 
lung ADs, even its overexpression is correlated with the advanced pathologic 
stage and shorter survival rates in lung AD patients. Taken together, Cav-1 
may serve as a suppressor in the early stage, while it shift its function in the 
later stage of lung adenocarcinoma patients. However, Cav-1 overexpression 
was observed in lung SCC. Moreover, the relationship between Cav-1 and 
clinicopathologic parameters is still controversial in adenocarcinoma and SCC. 
Therefore, the function of Cav-1 in lung cancer is histotype dependent. 
 
Bladder  
Hypermethylation of the Cav-1 promoter was found in bladder SCC by 
comparison with ADs, non-neoplastic urothelium. However, IHC 
demonstrated that all the specimens exhibited a strong diffuse immunostaining 
in bladder SCC, suggesting that the aberrant methylation of Cav-1 promoter 
and abnormal protein expression of the Cav-1 are related to bladder SCC, 
whereas no expression of Cav-1 can be detected in the normal transitional cell 
epithelium and adenocarcinomas, supporting epigenetic control of Cav-1 gene 
is not involved in the histogenesis of adenocarcinomas 
 
Abbreviations: ADs, adenocarcinomas; Cav-1, caveolin-1; EAC, esophageal adenocarcinoma; ESCC, 
esophageal squamous cell carcinoma; NMV, normalized methylation value; SCC, squamous cell carcinoma 
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TABLE – 3: The different functions of Cav-1 in human Squamous cell 
carcinoma (SCC) [Fu et al. 2017] 
Organ Tumour Stromal 
 Function Prognosis  
 
Function Prognosis 
skin 
Cav-1 serves as a tumor 
inhibitor in the progression of 
cutaneous SCC 
   
Oral 
 
 
The tumor-promoting 
function or tumor-
inhibiting function, even 
the biphasic functions of 
Cav-1 in OSCC still 
remains controversial. 
 
 
Cav-1 serves as a 
prognostic marker for 
poor prognosis in 
OSCC 
 
The stromal Cav-1 
serves as a tumor 
suppressor in OSCC 
 
 Tongue  
 
Cav-1 may serve as an 
oncogene in the development of 
tongue SCC 
 
Whether Cav-1 can 
predict the prognosis 
still need the 
extension of clinical 
studies. 
The stromal Cav-1 
plays a tumor-
promoting role in the 
progression of 
tongue SCC 
The accumulation of  
Cav-1 in TME is 
associated with poor 
prognosis. 
Throat 
 
Cav-1 plays a tumor-inhibiting 
role in larynges SCC via the 
negative regulation of the 
EGFR–MAPK signaling 
pathway, whereas the increased 
expression of Cav-1 means a 
worse DSS 
 
Cav-1 cannot serve as 
an independent 
prognostic factor for 
DSS. 
 
  
Head and 
neck 
 
Increased expression Cav-1 
promotes tumor cell migration 
and metastasis, indicating the 
tumor-promoting function in the 
progression of 
HNSCC..However, Cav-1 may 
have the potential to suppress 
tumorigenesis 
   
Esophagus 
 
Cav-1 expression is upregulated 
during ESCC carcinogenesis, 
whereas Cav-1 may function as 
a tumor inhibitor in ESCC 
 
The overexpression of 
Cav-1 correlates with 
poor prognosis in 
ESCC 
 
The decreased 
expression of Cav-1 
may promote 
malignant 
progression and 
heralds worse 
outcome 
The absence of 
stromal Cav-1 is 
closely related to the 
poor prognosis in 
ESCC 
 
Lung 
 
 
The tumor-promoting function 
has been observed in lung SCC 
 
Cav-1 can predict a 
poor prognosis in lung 
SCC. 
  
Bladder 
 
Cav-1 can drive tumorigenesis 
in bladder SCC 
   
Uterine 
 
Cav-1 may function as an 
oncogene in the development of 
cervical SCC,18 and Cav-1 
plays a vital role in cervical 
SCC invasion and 
metastasis.155 However, the 
tumor-inhibiting role of Cav-1 
also has been found 
  
Further studies are 
needed to determine 
the role of stromal 
Cav-1, which acts as 
a suppressor or 
promoter in cervical 
SCC 
 
Abbreviations: BAC, Barrett esophageal adenocarcinoma; Cav-1, caveolin-1; DSS, disease-specific survival; ESCC, esophageal squamous 
cell carcinoma; EGFR-MAPK, epidermal growth factor receptor-mitogen-activated protein kinase; HNSCC, head and neck squamous cell 
carcinoma; OSCC, oral squamous cell carcinoma; SCC, squamous cell carcinoma; TME, tumor microenvironment 
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EXPRESSION OF CAVEOLIN-1 IN SARCOMAS 
Cav-1 shows increased expression in sarcomas by expressing  in fibroblasts, 
smooth muscle cells, adipocytes and endothelial cells with a fine granular membranous 
and a diffuse cytoplasmic staining pattern.[Wiechen et al. 2001]. 
Various other studies focusing on the expression of cav-1 in specific sarcomas 
have shown that this protein is expressed in the cytoplasm of cells of the mesenchymal 
benign tumors, including the adipocyte of all types of lipoma and well-differentiated 
liposarcoma, the myocyte of angiomyolipoma, leiomyoma, and well differentiated 
leiomyosarcoma. The immunostaining properties appeared uniform among these lesions, 
with no implication on the gender and age. Conversely, the malignant mesenchymal 
tumors which are poorly differentiated and dedifferentiated, including leiomyosarcoma 
and liposarcoma, showed weak immunoreactivity or failed to stain with cav 1, suggesting 
thatloss of cav 1 might be a necessary step towards a differentiation.[Garner et al. 2002] 
Cav-1 was identified as a metastasis associated gene that is a transcriptional target 
of EWS/FLI1 (Ewing‟s sarcoma / friend leukemia integration 1 transcription factor) as 
well as an important determinant of  Ewing‟s sarcoma family of tumors,  malignant 
phenotype and tumorigenicity [Tirado et al. 2006] 
Cav-1 promotes the malignant phenotype in Ewing‟s sarcoma carcinogenesis 
[Jaspeado et al. 2011] 
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EXPRESSION OF CAVEOLIN-1 IN TUMORS OF ORAL AND 
PARAORAL REGION 
Expression of Caveolin -1 in Normal Oral Tissue 
Schwab, et al in 2007 reported cav- 1 expression in epithelial and mesenchymal 
cells of tooth germ in various stages of development, particularly in the inner enamel 
epithelium and ameloblastic cells in developing tooth germ and suggesting that cav-1 
could participate in odontogenesis.  
Kashyap et al in 2016 found that Cav-1 is highly expressed in epithelial cells 
including keratinocytes, salivary glands and respiratory tract epithelium, as well as, 
osteoblasts, endothelial cells and skeletal muscle.   
Cav-1 is strongly expressed in the ductal epithelial cells of normal salivary glands 
but the physiologic function of caveolae and cav-1 in normal salivary gland is yet to be 
elucidated. [Kashyap et al. 2016] 
Expression of Caveolin -1 in salivary gland tumors 
Ashkavandi et al in 2015 evaluated and compared the expression of Cav-1 in 
benign and malignant salivary gland tumors and evaluated its correlation with 
proliferation activity. Immunohistochemical expression of caveolin-1 and Ki67 were 
evaluated in 49 samples, including 11 normal salivary glands, 15 cases of pleomorphic 
adenoma (PA), 13 adenoid cystic carcinomas (AdCC), and 10 mucoepidermoid 
carcinomas (MEC). The expression of Cav-1 was seen in 18 % of normal salivary glands 
and 85 % of tumors. Overexpression of Cav-1 was found in salivary gland tumors in 
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comparison with normal tissues, but no significant difference was observed between 
benign and malignant tumors. 
Tumor specimens from 75 patients with previously untreated MEC of the salivary 
glands were collected. Immunohistochemical analysis revealed a strong, diffuse, 
cytoplasmic staining pattern in of caveolin-1 expression in the ductal epithelial cells in all 
20 normal salivary gland samples .Forty one samples (54.7%) of MEC showed a fine, 
granular pattern at the surface membrane and the cytoplasm of cancer cells. Reduced 
expression of caveolin-1 was noted in 34 samples (45.3%).Down-regulated caveolin-1 
expression was associated with advanced clinical stage, high-grade malignancy of MEC, 
and development of recurrent disease. The frequency of caveolin-1 expression was higher 
in the tumors that had longer duration (68%) compared with tumors that had shorter 
duration (44%), indicating that tumor suppressor characteristics of caveolin-1 retarded 
the progression of tumors and prolonged their duration. Caveolin-1 may serve as a tumor 
suppressor in MEC of the salivary glands. [Shi et al., 2007] 
Expression of cav-1 in Odontogenic cysts and Tumors 
Ashkavandi et al in 2014 evaluated the caveolin-1 expression in 75 samples 
including 18 cases of dentigerous cyst, 18 odontogenic keratocysts, 3 orthokeratinized 
odontogenic cysts, 2 calcifying odontogenic cysts and 34 ameloblastomas (solid and 
unicystic) and found positive immunohistochemical reaction in 100% of odontogenic 
cysts and this was significantly more than both unicystic (65%) and solid (55%) 
ameloblastomas. Membranous and cytoplasmic immunoreactivity was observed 
throughout the basal cell layer of all cysts. In the luminal unicystic ameloblastoma, the 
basal ameloblast-like cells were positive. Superficial epithelial cells were stained in a few 
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cases. Mural and solid ameloblastomas showed immunoreactions in the peripheral 
ameloblast-like cells of the tumoral nest. The author suggests that Cav-1 could have a 
tumor suppressor finding in odontogenic tumors. 
Expression of Caveolin -1 in OSCC and Verrucous carcinoma 
Cav-1 participates in oncogenic transformation and differentiation in oral 
squamous cell carcinoma [Williams TM, Lisanti MP. 2005] 
Hung et al in 2003 and Xue et al in 2010 reported that an increased Cav-1 
expression correlates with the carcinogenesis in a stepwise manner from the normal oral 
mucosa and oral precancerous lesions to primary oral SCC (OSCC); however, the 
decrease in the expression from the primary OSCC to metastatic OSCC did indicate the 
necessity of exploring its dual functions in oral carcinogenesis. 
Nakatani et al in 2005 assessed the role of Cav-1 with both metastasis and 
multidrug resistance and its chemosensitivity in oral squamous cell carcinoma and 
analyzed expression of Cav-1 in 30 OSCC biopsy specimens. Cav-1 expression was also 
determined by reverse transcriptase-polymerase chain reaction (RT-PCR) using cisplatin 
(CDDP)-resistant cell line,   H-1R, from the parental OSCC cell line, H-1 
Immunohistochemical staining of Cav-1 correlated positively with chemosensitivity to 
CDDP-based combination chemotherapy suggesting that overexpression of the caveolin-
1 gene may provide as a novel diagnostic marker. 
Ashkavandi et al 2017 evaluated Cav-1 expression in OLP in comparison with 
12 cases of hyperkeratosis, 24 OLP, 22 epithelial dysplasia, and 23 OSCC samples to 
investigate its possible role in pathogenesis and malignant transformation of OLP and 
found Cav-1 positivity in 58% of OLP, 91% of hyperkeratosis, 100% of epithelial 
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dysplasia, and 95% of OSCC samples. Cav-1 expression was highest in OSCC and 
lowest  in OLP. The intensity of staining was significantly increased in stepwise manner 
from OLP to OSCC and concluded that Cav-1 may play a role in the pathogenesis of 
OLP and carcinogenesis of SCC, but its role in malignant transformation of OLP was not 
confirmed. 
The role of Cav-1 in OSCC still remains complex and controversial. Cav-1 
overexpression is observed in the cytoplasm of OSCC by comparison with normal oral 
mucosa and serves as a prognostic marker for poor prognosis in OSCC. Moreover, Cav-1 
upregulation plays an important role in the tumor progression and correlates with 
cisplatin sensitivity in OSCC. Cav-1 downregulation was found in other studies, and 
genetic evidence showed the inactivation of Cav-1 by a mutation or reduced expression 
may take effect in the pathogenesis of OSCC. An increased Cav-1 expression that was 
observed stepwise in carcinogenesis from normal oral mucosa (8%), noncancerous-
matched tissues (18%), oral precancerous lesions (53%) to primary OSCC (79%), a 
drastic decrease in expression from primary OSCC to metastatic OSCC (37%), which 
indicates the value to explore its biphasic functions in oral carcinogenesis.[Hung et al. 
2003] 
In the tumor stroma, a reverse Warburg metabolism in OSCC is not dependent 
upon myofibroblasts, and no negative correlation is detected between the loss of stromal 
Cav-1 expression and the elevated expression of MCT4, which has been shown in breast 
cancer. Furthermore, the reduced Cav-1 can lead to an increase in oxidative stress in 
OSCC microenvironment [Fu et al. 2017] 
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A search of the available English language literature showed that till date no 
attempt has been made to identify the significance of Caveolin-1 in verrucous carcinoma. 
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SOURCE AND COLLECTION OF DATA: 
This study was conducted on archival tissue samples of histopathologically 
confirmed cases of veruccous carcinoma and squamous cell carcinoma taken from the 
Department of Oral Pathology & Microbiology, KSR Institute of Dental Science and 
Research, Thiruchengode. This laboratory study comprised of a total of 60 samples in 
which 30 samples were of well differentiated oral squamous cell carcinoma, 30 samples 
were Verrucous carcinoma (n=30). These archival tissues were fixed in neutral buffered 
formalin and embedded in paraffin wax. 
 
INCLUSION CRITERIA 
 Tissue blocks of histopathologically diagnosed cases of Verrucous carcinoma and  
well differentiated oral squamous cell carcinoma 
 
EXCLUSION CRITERIA 
 Tissue blocks of above mentioned cases, with inadequate tissue 
 Cases lacking in relevant clinical data 
 
All the 60 cases were subjected to immunohistochemical staining to evaluate the 
expression of  Caveolin-1. Blood vessels are used as internal positive control. 
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EQUIPMENTS AND MATERIALS USED IN THE STUDY: 
Apart from equipments and materials required for routine processing of soft 
tissues, the following equipments and materials were used for the immunohistochemical 
staining. 
1. APES (3-Aminopropyltriethoxysilane) pre coated slides 
2. Microtome 
3. Xylene 
4. 100%, 90%, 70%, and 50% alcohol 
5. Distilled water 
6. Citrate buffer(pH: 6) 
7. Pressure cooker 
8. Humidifying chamber 
9. Micropipettes with plastic disposable pipette tips 
10. Tris phosphate wash buffer (pH: 7.4) 
11. Primary antibody – Rabbit Polyclonal Anti-Caveolin-1 Antibody ( Abcam ) 
                 [1:1000 dilution] 
12. Universal kit was based on labeled streptavidin biotin method 
- 3% hydrogen peroxide block 
- Biotinylated secondary antibody 
- Streptavidin conjugated with horse radish peroxides 
- Diluting buffer 
- Diaminobenzidine chromogen (DAB) 
13. Harris Hematoxylin 
14. Mountant 
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15. Cover slip 
16. Slide holding box 
17. Light microscope (OlympusCH20i) 
 
PREPARATION OF PRIMARY ANTIBODY: 
Primary antibody Caveolin-1 
    Rabbit polyclonal antibody to Caveolin-1: This primary antibody was diluted to 
a ratio of 1:1000 using antibody diluent solution (Abcam, US) 
 
PREPARATION OF BUFFERS:  
Antigen retrieval buffer - Sodium citrate buffer (10millimoles Sodium citrate, pH 
6.0) 
 Tri-sodium citrate (dihydrate)-2.94g 
 Distilled water-1000ml 
 1Mol hydrochloric acid-5ml 
 All the above ingredients were mixed to dissolve. The pH was adjusted to 6.0 
with 1 mol hydrochloric acid. 
Wash buffer - Tris buffer saline (TBS, pH 7.4) 
 Tris - 0.605gms 
 Sodium chloride - 8gms 
 1Mol Hydrochloric acid - 4.4ml 
 All the above ingredients were mixed to dissolve. The pH was adjusted to 7.4 
with 1 mol hydrochloric acid. 
                                                       MATERIALS AND METHODOLOGY 
 
41 
 
METHODOLOGY 
IMMUNOHISTOCHEMICAL STAINING: 
Sectioning: 
For immunohistochemistry, each section of about 3 to 4 μm thickness was 
prepared by using a semiautomatic microtome. The sections were placed on APES 
precoated slides. The slides were preserved in a slide holding box until they were stained. 
Deparaffinization: 
The sections were deparaffinized by heating on the slide warmer at 60°C for one 
and half hours. The sections were then dewaxed in 2 changes of xylene, each lasting 15 
minutes. 
Rehydration: 
The sections were rehydrated in decreasing grades of alcohol (100%, 90%, 70%, 
and 50%), 5 minutes each and kept under water for 10 minutes. 
Antigen Retrieval: 
 1.5 liters of Sodium citrate buffer ( pH 6.0) was added into the pressure cooker 
and brought to boil (without securing the lid) 
 Once the buffer started boiling the slide racks were placed into the hot buffer and 
the lid was sealed 
 Then the pressure cooker was allowed to reach the full pressure, then left for 
about 20 minutes 
 The pressure cooker was cooled until all the pressure was released 
 The slides were removed and then rinsed twice with Tris buffer saline (pH 7.4) 
for 5 minutes.  
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IHC STAINING PROCEDURE: 
All the reagents stored in the refrigerator were brought to room temperature prior 
to immunostaining. All the incubations were performed at room temperature using a 
humidifying chamber. The tissue sections were not allowed to dry at any point during the 
staining procedure. 
 
Step 1: Endogenous peroxidase blocking: 
The sections were covered with peroxidase block for 10 minutes to prevent non 
specific binding of antibody. Then slides were rinsed twice with wash buffer for 5 
minutes. 
 
Step 2: Power Block: 
Antibodies may attach non specifically to highly charged sites. Hence to avoid 
this, power block was used to avoid cross reactions and to reduce non specific binding. 
The sections were covered with power block solution for 10 minutes. 
 
Step 3: Incubation with primary antibody: 
Excess buffer was tapped off and the sections were covered completely with 
rabbit polyclonal Anti-Caveolin-1 Antibody (1:1000 dilution, Abcam) at 21°C 
temperature for 2 hours. The sections were washed in two changes of wash buffer 
thoroughly for 5 minutes each. In each batch, one section to which primary antibody was 
not added served as a negative control. 
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Step 4: Super enhancer application 
The sections were covered with super enhancer for 20 minutes and washed with 
tris buffer for 5 minutes each and excess was wiped out using blotting paper. 
 
Step 5: Secondary antibody application: 
The slides were washed and treated with secondary antibody tagged with Poly 
Horseradish peroxidase enzyme (HRP) for 30 min. [Biogenex] 
 
Step 6: Substrate chromogen application: 
The slides were then washed with phosphate buffer saline and immunostaining 
was developed by treatment with freshly prepared DAB (3-diaminobenzidene tetra 
hydrochloride) solution for 5 minutes following which it was washed in distilled water to 
remove excess chromogen. 
 
Step 7: Counter stain: 
The slides were immersed in Harris hematoxylin for 7 minutes, and bluing was 
done in running tap water for 10 minutes 
 
Step 8: Dehydration and cleaning: 
The sections were dehydrated in 100% alcohol, followed by clearing in xylene. 
 
Step 9: Mounting: 
The sections were mounted using media Dibutyl Pthalate Xylene (DPX), a non-
aqueous permanent mounting medium. 
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INTERPRETATION OF STAINING: 
 Presence of brown colored end product at the site of target antigen (membrane 
and cytoplasmic positivity) was considered as positive immunoreactivity. 
 The immunostained slides were observed in a bright field microscope at a 
magnification of 40X in randomly selected 5 fields to analyze the percentage of 
cells showing positivity and the color intensity as well. 
 The staining was scored by evaluating the positive and negative immunoreactivity 
of each slide.  
 High quality photomicrographs were taken from different representative areas. 
 
IMMUNOREACTIVE SCORING 
Semi quantitative analysis of stained cells was done according to immunoreactive score 
(IRS) by Remmele and Stegner, but this was modified with regard to grading of positive 
cells, in which the percentage of positive cells varied for each grade, when compared 
with Remmele and Stegner criteria. 
 
 Percentage of positive cells (A) were graded on a point scale, as follows:- 
 0 point = No expression 
 1 point = 1 to 25% of positive cells 
 2 points = 26 to 50% of positive cells 
 3 points = 51 to 75% of positive cells 
 4 points = 76 to 100% of positive cells 
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 Intensity of the staining (B) was graded on a point scale, as follows :- 
 0 point = No color reaction 
 1 point = Mild color reaction 
 2 points = Moderate color reaction 
 3 points = Intense color reaction 
 Final analysis was done using the following criteria. Final immunoreactive 
scoring (0-12 points) was given by multiplying the points obtained in A and B 
analysis, and corrected to the nearest integer. 
 0 -1 point = Negative 
 2-3 points = Mild 
 4-8 points = Moderate 
 9-12 points = Strongly positive 
STATISTICAL METHODS 
 All the parameters were tabulated and assessed for statistical significance using 
Statistical Package for Social Science (SPSS) software. 
 Data analysis was performed using T - test to correlate the percentage of 
positivity, intensity of staining and IRS score of Caveolin-1 expression in 
verrucous carcinoma and oral squamous cell carcinoma. 
 The level of significance (p <0.05) was employed in all statistical comparisons. 
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ARMAMENTARIUM :  
 
Figure 1: Photograph showing materials used during IHC  staining procedures 
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FIGURE 2: Photograph showing anti Caveolin – 1 primary antibody  
 
FIGURE 3: Photograph showing universal secondary antibody kit.   
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A total of 60 cases, comprising 30 cases of verrucous carcinoma [Group I] and 30 cases 
of oral squamous cell carcinoma [Group II] were evaluated for Caveolin-1expression. 
The distributions of cases were presented in table 1. 
 
TABLE 1: THE DISTRIBUTION OF CASES AMONG THE TWO STUDY 
GROUPS 
 
Groups 
 
 
Number of cases 
 
 
Verrucous carcinoma 
 
 
30 
 
 
Oral squamous cell carcinoma 
 
 
30 
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TABLE 2 : COMPARISON OF IMMUNOREACTIVE SCORE [IRS] OF 
CAVEOLIN-1 EXPRESSION IN VERRUCOUS CARCINOMA AND ORAL 
SQUAMOUS CELL CARCINOMA: 
 
CAVEOLIN-1 
EXPRESSION 
(IRS) 
Verrucous 
carcinoma 
Oral squamous cell 
carcinoma 
 
NEGATIVE 
 
 
2 
 
2 
 
MILD 
EXPRESSION 
 
 
10 
 
14 
 
MODERATE 
EXPRESSION 
 
 
10 
 
11 
 
STRONG 
EXPRESSION 
 
 
8 
 
3 
 
 
In the present study, Out of 30 case of Verrucous Carcinoma, the IRS of 
Caveolin-1 expression was found to show a negative expression  in 2 cases; mild 
expression in 10 cases, moderate expression in 10 cases; strong expression in 8 cases. Out 
of 30 case of OSCC, the IRS of Caveolin-1 expression was found to show a negative 
expression  in 2 cases; mild expression in 14 cases, moderate expression in 11 cases; 
strong expression in 3 cases.  
 
Note: The percentage of positivity and intensity of staining of Verrucous carcinoma and 
squamous cell carcinoma of all the cases are presented in Annexure. 
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TABLE 3 : COMPARISON OF PERCENTAGE OF POSITIVITY OF 
CAVEOLIN-1 EXPRESSSION BETWEEN VERRUCOUS CARCINOMA AND 
ORAL SQUAMOUS CELL CARCINOMA 
 
Groups 
Number 
of cases 
Mean P VALUE Inference 
Verrucous 
carcinoma 
30 2.3933 
0.121 
NOT 
SIGNIFICANT Oral squamous cell 
carcinoma 
30 2.0067 
 
 
Percentage of positivity of two groups was compared. Mean value of percentage of 
positivity cav-1 expression in verrucous carcinoma was 2.3933 and in squamous cell 
carcinoma was 2.0067. Comparison of these two groups for percentage of positivity was 
done by using T-test and found to be not statistically significant. (p value= 0.121). 
 
 
TABLE 4 : COMPARISON OF INTENSITY OF STAINING OF CAVEOLIN-1 
EXPRESSSION BETWEEN VERRUCOUS CARCINOMA AND ORAL 
SQUAMOUS CELL CARCINOMA 
 
 
Groups 
Number 
of cases 
Mean P VALUE Inference 
Verrucous 
carcinoma 
30 1.9133 
0.816 
NOT 
SIGNIFICANT Oral squamous cell 
carcinoma 
30 1.8667 
 
Intensity of staining of two groups was compared. Mean value of intensity of staining of 
cav-1 expression in verrucous carcinoma was 1.9133 and in squamous cell carcinoma 
was 1.8667. Comparison of these two groups for intensity of staining was done by using 
T-test and found to be not statistically significant. (p value - 0.816). 
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TABLE 5 : COMPARISON OF IMMUNOREACTIVE SCORE OF CAVEOLIN-1 
EXPRESSSION BETWEEN VERRUCOUS CARCINOMA AND ORAL 
SQUAMOUS CELL CARCINOMA 
 
Groups 
Number 
of cases 
Mean P VALUE Inference 
Verrucous 
carcinoma 
30 5.3667 
0.111 
NOT 
SIGNIFICANT Oral squamous cell 
carcinoma 
30 4.1000 
 
Immunoreactive score of two groups was compared. Mean value of immunoreactive 
score of cav-1 expression in verrucous carcinoma was 5.3667 and in squamous cell 
carcinoma was 4.1000. Comparison of these two groups for immunoreactive score was 
done by using T-test and found to be not statistically significant. (p value= 0.111). 
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Figure 4: Photomicrograph of immunopositivity for Cav-1 in Verrucous carcinoma showing 1 to 
25% of positivity and mild staining intensity. (4x) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Photomicrograph of immunopositivity for Cav-1 in Verrucous carcinoma showing 26 to 
50% of positivity and moderate staining intensity. (4x) 
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Figure 6: Photomicrograph of immunopositivity for Cav-1 in Verrucous carcinoma showing 51 to 
75% of positivity and moderate staining intensity. (10x) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Photomicrograph of immunopositivity for Cav-1 in Verrucous carcinoma showing 76 to 
100% of positivity and intense staining intensity. (4x) 
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Figure 8: Photomicrograph of immunopositivity for Cav-1 in Well differentiated oral squamous 
cell carcinoma showing 1 to 25% of positivity and mild staining intensity. (10x) 
 
 
 
 
 
 
 
 
 
 
Figure 9: Photomicrograph of immunopositivity for Cav-1 in Well differentiated oral squamous 
cell carcinoma showing 26 to 50% of positivity and intense staining intensity. (4x) 
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Figure 10: Photomicrograph of immunopositivity for Cav-1 in Well differentiated oral squamous 
cell carcinoma showing 51 to 75% of positivity and moderate staining intensity. (4x) 
 
 
 
 
 
 
 
 
 
 
Figure 11: Photomicrograph of immunopositivity for Cav-1 in Well differentiated oral squamous 
cell carcinoma showing 76 to 100% of positivity and moderate staining intensity. (4x) 
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Caveolin-1 is the main protein that participates in formation of caveolae that are 
50-100 nm omega-shaped invaginations of the plasma membrane [Hung et al., 2003]. 
Caveolae are primarily formed by caveolin proteins including cav-1, 2, and 3 [Lajoie P 
et al., 2010].  
 They have a loop structure with common topology consisting of  Cytoplasmic N-
terminus with scaffolding domain, cytoplasmic C-terminus, and a long transmembrane 
domain [Lajoie P et al., 2010]. They can move into cytoplasm and return to cell surface 
[Liu P et al., 2002]. 
Caveolins are found predominantly at the plasma membrane but also in the Golgi, 
the endoplasmic reticulum, in vesicles, and at cytosolic locations [Williams TM., 2005]. 
 Caveolin-1 is highly expressed in epithelial cells including keratinocytes, salivary 
glands and respiratory tract epithelium, as well as, osteoblasts, endothelial cells and 
skeletal muscles; epithelial and mesenchymal cells of tooth germ in various stages of 
development [Liu P et al., 2002]. Cav-1 expression has also been noticed in enamel 
organ, especially inner enamel epithelium and ameloblast cells of developing tooth germ. 
 Studies had shown that some signaling molecules are related to the caveolin-
scaffolding domain (CSD) [Williams TM., 2005] and some roles are determined for cav-
1 including prevention of cells cycle progression via saving the cell cycle in G0/G1 stage, 
[Keisuke N et al., 2008] cell transformation, programming cell death by activating 
protein kinase B (PKB) pathway [Li L et al., 2003] and acting as an oncogene or tumor 
suppressor gene based on the tumor type and stage [Williams TM., 2005]. Also, it is 
shown that cav-1 can delay tumor metastasis by decreasing of matrix metalloproteinases 
(MMP) secretion [Ashkavandi et al., 2014]. 
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Several studies have been made to identify the role of Caveolin-1 expression in 
different carcinomas which includes breast [Savage k et al., 2007, Simpkins S A et al., 
2012 & Patani N et al., 2012], gastrointestinal carcinoma [Juhasz et al., 2003], 
hepatocellular carcinoma [Tse Y T et al., 2012], lung carcinoma [Seong-Ho Yoo et al., 
2003, Kato T et al., 2004 & Chao-Chi Ho et al., 2008], ovarian carcinoma [Davidson B 
et al., 2001], pancreatic carcinoma [Suzuoki et al., 2002 & Tanase C P et al., 2009], 
carcinoma of thyroid [Ito Y et al., 2002] and prostate carcinoma [Yang G et al., 1999; 
Satoh T et al., 2003 & Ayala G et al., 2013]. 
Hung et al., 2003, Nakatani et al., 2005,  Xue et al., 2010, Ashkavandi et al., 
2017 studied the expression of Cav-1 in oral squamous cell carcinoma. 
In this study, Caveolin-1 expression was evaluated in verrucous carcinoma and in 
oral squamous cell carcinoma. This study comprised of a total of 60 samples in which 30 
samples were verrucous carcinoma and 30 samples were of well differentiated oral 
squamous cell carcinoma, which were all selected from the archives of Oral and 
Maxillofacial Pathology Department. 
Immunostaining was done using the rabbit monoclonal Anti-Caveolin-1 antibody. 
Caveolin-1 (Abcam-USA). Caveolin-1 expression was evaluated by using semi 
quantitative analysis of stained cells. The scoring was done, largely following the method 
of immuno reactive score (IRS) by Remmele and Stegner, but it was modified in that 
the percentage of positive cells (A) were graded on a point scale, as follows:-                   
0 point = No expression, 1 point = 1 to 25% of positive cells, 2 points = 26 to 50% of 
positive cells, 3 points = 51 to 75% of positive cells, 4 points = 76 to 100% of positive 
cells. Intensity of the staining (B) was also graded on a point scale as follows: -                         
0 point = No color reaction,1 point = Mild color reaction, 2 points = Moderate color 
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reaction, 3 points = Intense color reaction and the final analysis was done using the 
following criteria. Final IRS score (0-12 points) was given by multiplying the points 
obtained in A and B analysis, and corrected to the nearest integer. The obtained IRS score 
was categorised as follows:- 0 -1 point = Negative,2-3 points = Mild, 4-8points = 
Moderate, 9-12 points = Strongly positive. The results obtained in verrucous carcinoma 
and oral squamous cell carcinoma were tabulated and analyzed statistically using T – test. 
In our study, all the cases of squamous cell carcinoma showed positive 
expression. This is in accordance with Ashkavandi et al., who observed 96% of cases 
showing positive expression in SCC cases and in contrast to Hung et al who observed 
63% of cases showing positive expression in SCC cases. 
The mean value of percentage of positive cells in scc cases of our study is 2.0 
This is in sharp contrast to the findings derived by Ashkavandi et al.,who noticed the 
mean value of percentage of positive cells in scc to be 80. The methodology used to 
quantify the positive cells in our study differs from that of Ashkavandi et al. In our study 
5 randomn fields were taken and number of cells which have stained positively for Cav-1 
was quantified in the following manner. 0 point = No expression, 1 point = 1 to 25% of 
positive cells, 2 points = 26 to 50% of positive cells, 3 points = 51 to 75% of positive 
cells, 4 points = 76 to 100% of positive cells. Ashkavandi et al estimated the percentage 
of positive cells in 1000 cells of each case at x400 magnification. Stained samples were 
classified as: negative (<10% staining), 1+ (10% - 25% staining), 2+ (26% - 50% 
staining), 3+ (51% -75% staining), 4+ (76% - 100% staining). The mean of positive cells 
was also calculated in the basal layer of epithelium or peripheral cells of tumoral nests, 
and suprabasal layer or central cells of tumoral nests, separately. Hence the difference in 
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the results may be partly explained by difference in the quantification method used and 
areas chosen for quantification. 
Quantification of Cav-1 expression in oral squamous cell carcinoma was observed 
by Hung et al., who used a totally different methodology. He had quantified percentage 
of positivity of cav-1 expression in five random fields and categorized as follows, <10% 
cells – negative, 10-50% cells – (cav +) and over 50% - (cav ++). From the results of this 
study, its inferred that 80% cells showed cav+ and 20% of cells showed cav++. Thus the 
two available study for comparision is different from each other in the quantification 
method from that of our study. Hence, the significance of the findings in our study  
cannot be compared. 
The number of cases which showed intense expression in our study is 13% which 
is in contrast to the findings derived by Ashkavandi et al. They noticed that 92% of  
cases showing a high score for intensity. 
The intensity of staining is different from our findings probably because he has 
graded the intensity as high and low whereas in this study the intensity was graded as 
mild, moderate or intense expression. If moderate and intense is taken as equivalent to 
high score then the intensity increases to 40%. Still the intensity of staining observed in 
this study is less and that can be due to the difference in the dilution of primary antibody 
which was 1:200 by Ashkavandi et al whereas it was 1:1000 in our study No other study 
is available for comparison for percentage of positivity and intensity of staining of Cav-1 
in oral squamous cell carcinoma. 
The IRS in our study (which is the product of percentage of positivity and 
intensity of staining) is expectedly different from that of Ashkavandi et al, because of 
the different methodology and the difference in primary antibody used for the appraisal. 
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All slides of SCC were assessed for the extent of staining from basal layer to the 
cornified layer of the epithelium. We found that almost all samples, showed positivity 
from basal to spinous layer and islands of squamous cell carcinoma shows more staining 
in peripheral cell layers compared to central portion, whereas keratin pearl and individual 
cell keratinisation were not stained. Our findings are similar to the findings of 
Ashkavandi et al., who observed more staining percentage of cells in the peripheral cell 
layers when compared with central portions. Central area of large sheets and the cells 
around the keratin pearls and individual cell keratinization were not stained. Small cords 
and nests were completely stained.  
Caveolin-1 expression was also studied in 30 cases of verrucous carcinoma. All 
the cases of verrucous carcinoma showed positive expression. The mean value of 
percentage of positivity (PP) of verrucous carcinoma was 2.4; mean value of intensity of 
staining was 1.9 and mean value of immunoreactive score was 5.4. 
All slides of verrucous carcinoma cases were assessed for the extent of staining 
from basal layer to the cornified layer of the epithelium. We found that almost all 
samples of verrucous carcinoma group showed positive staining from basal layer to 
granular layer. 
Using the keywords: Caveolin-1, CAV-1, Verrucous carcinoma, Oral verrucous 
carcinoma in Google and Pubmed search, no published study was available for 
expression of Caveolin-1 in verrucous carcinoma. 
Comparing the expression of cav-1 in verrucous carcinoma and squamous cell 
carcinoma in this study, it was observed that , the mean percentage of positivity score 
was found to gradually decrease from verrucous carcinoma group to OSCC group. (Mean 
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PP score in verrucous carcinoma - 2.4; OSCC - 2.0).This decrease in PP score was not 
significant statistically. (P = 0.121) 
Although the difference was not significant statistically, we can interpret that the 
number of cells taking up Cav-1 decreases from verrucous carcinoma; which can be 
considered as a malignancy of lesser potential, to squamus cell carcinoma, which is a 
malignancy of higher potential.  
Ashkavandi et al., 2017 in their study on Caveolin-1 expression in oral lichen 
planus, dysplastic lesions and squamous cell carcinoma found that Cav-1 was increased 
with increasing severity of lesion. But the difference was not statistically significant. 
Similarly, Hung et al., in 2003 and  Xue et al., in 2010  noticed an increased cav-1 in a 
stepwise manner from normal oral mucosa, oral precancerous lesions proceeding till 
primary oral squamous cell carcinoma. This is in contrast to our findings where the 
number of positive cells decreases as the severity of lesion increases (i.e) from verrucous 
carcinoma ( a malignanc of lower potential ) to squamous cell carcinoma ( a malignanc of 
higher potential). 
The Intensity Of Staining (IOS) was assessed in both verrucous carcinoma and 
squamous cell carcinoma groups. We found that, there was no significant difference in 
IOS score among these groups. Both the groups showed mild, moderate and severe 
intensity of Cav-1 expression. In verrucous carcinoma, 43% of cases showed intense 
staining, 31% showed moderate staining and 26% showed mild staining suggesting that 
more cases showed intense staining. In squamous cell carcinoma, 36% of cases showed 
intense staining, 47% showed moderate staining and 17% showed mild staining 
suggesting that more cases showed moderate staining. By this finding, we observed that 
more number of verrucous carcinoma cases showed more intense staining when 
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compared to squamous cell carcinoma; correlating with more expression of Cav-1 in 
Verrucous carcinoma. 
Ashkavandi et al., 2017 in their study also evaluated the staining intensity for 
Cav-1 in lichen planus, hyperkeratosis, dysplasia and squamous cell carcinoma. They 
found that 69.2% of the dysplasia samples showed the staining intensity of ++ (moderate 
staining). However in other study groups (Hung et al., in 2003 & Xue et al., in 2010), 
grading of intensity of staining was not observed. But they stated that, with increase in 
severity of lesion, intensity of staining also increased. This finding is not in accordance 
with this study where it was noted that decrease in intensity of cav-1 expression occurs 
with increase in severity of lesion. 
The Immuno Reactive Score (IRS) for each sample was obtained by multiplying 
Percentage of Positivity (PP) with Intensity Of Staining (IOS). Theoretically IRS values 
can range from 0 to 12. However we noticed that mean IRS was 5.4 in verrucous 
carcinoma and 4.1 in oral squamous cell carcinoma. This shows that there is decline in 
IRS as the severity of lesion increases.  
All slides were assessed for the extent of staining from basal layer to the cornified 
layer of the epithelium. We found that almost all samples, in both scc and verrucous 
carcinoma groups showed positivity from basal to spinous layer and islands of squamous 
cell carcinoma shows more staining in peripheral cell layers compared to central portion, 
whereas keratin pearl and individual cell keratinisation were not stained. However, 
verrucous carcinoma showed positive staining from basal layer to granular layer. This 
shows that as the severity of lesion increases, the peripheral layers of epithelium showing 
Cav-1 expression decreases. 
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The significance of the findings in this study in which the expression of Cav-1 in 
verrucous carcinoma and squamous cell carcinoma was compared could not be 
ascertained as there are no studies of Cav-1 in verrucous carcinoma. 
The role of Cav-1 in Oral carcinoma is highly controversial. Many studies [Hung 
et al., 2003 & Zhang et al., 2008] had implicated Cav-1 as a tumor suppressor. 
However, various other studies [Hung et al., 2003; Nakatani et al., in 2005;  Xue et al., 
2010 & Ashkavandi et al., 2017]  have also established that Cav-1 may participate in 
tumor progression and metastasis. 
Similar controversy exists with regard to Cav-1 expression on tumors of other 
organs. Many studies in carcinomas of different organs like breast [Savage k et al., 2017, 
Patani N et al., 2012; Simpkins S A et al., 2012], GIT [Juhasz et al., 2003], lung [Kato 
T et al., 2004], Ovary [Davidson B et al., 2001], & prostate [Ayala G et al., 2013] had 
implicated Cav-1 as a tumor suppressor, whereas various other studies in those organs 
like liver [Tse et al.,2012], lung [Seong-Ho Yoo et al., 2003], pancreas [M Suzuoki et 
al.,2002 & Tanase C P et al., 2009], thyroid [Ito Y t al., 2002] and prostate [Takefumi 
satoh et al., 2003] have established that cav-1 may act as an oncogene. 
Thus, Cav-1 has a diverse effects in different tissues and cells probably due to 
differential activation of different domains of Cav-1 or due to diverse molecules that 
interact with Cav-1. Any effect or significance of Cav-1 might therefore be substantially 
dependant on other molecules also. The findings in the study which is in contrast to 
studies of Ashkavandi et al and Hung et al with regard to decrease in staining with 
increase in severity, can be explained on the basis of different domain of cav-1 which 
may get activated and the genetic defect that confer the capacity for differential Cav-1 
expression. 
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Our findings of highest immunoreactivity for Cav-1 in verrucous carcinoma when 
compared to squamous cell carcinoma suggest the concept that Cav-1 act as a tumor 
suppressor.  
Cav-1 has also been identified as a potential target for oxidative stress related 
changes in cells and tissues. 
Recent study by Wang et al., 2017  shown that Oxidative stress processes in 
cancer cells are closely associated with Cav-1. It has been noted that oxidative stress 
leads to a reduction of Cav-1 by modulating its expression and degradation. 
On contrary, studies have shown that decrease in Cav-1 promotes oxidative stress 
and mitochondrial dysfunction. Whether oxidative stress leads to Cav-1 loss or Cav-1 
suppression results in increased oxidative stress, is a subject of controversy. 
Our findings of decreased Cav-1 expression from verrucous carcinoma to 
squamous cell carcinoma supports the view that oxidative stress might play a role in  
Cav-1 suppression. This is significant since prolonged oxidative stress might play a role 
in malignant transformation or increasing the malignant potential of such lesions.  
Athough the difference in IRS is not statistically significant between Verrucous 
carcinoma and squamous cell carcinoma, yet the findings of decreased expression of 
Cav-1 in squamous cell carcinoma and increased expression in verrucous carcinoma 
observed in this study, opens up a new area of research. The significance of our finding is 
limited on account of small sample size of this study and the non availability of studies of 
Cav-1 in verrucous carcinoma. 
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SUMMARY 
In this study, Caveolin-1 expression was evaluated in verrucous carcinoma and in 
oral squamous cell carcinoma. This study comprised of a total of 60 samples in which 30 
samples were verrucous carcinoma and 30 samples were of well differentiated oral 
squamous cell carcinoma, which were all selected from the archives of Oral and 
Maxillofacial Pathology Department. 
Immunostaining was done using the rabbit monoclonal Anti-Caveolin-1 antibody. 
Caveolin-1 (Abcam- USA). The positivity of cells were graded as points 0.1,2,3,4 based 
on the % of cells positively stained.  The intensity of expression was evaluated under the 
following criteria as negative, mild, moderate and intense. Then the results were analyzed 
in verrucous carcinoma and oral squamous cell carcinoma using T-test. 
Following observations were made from this study: 
 In present study all the 60 cases both of squamous cell carcinoma and verrucous 
carcinoma showed positive staining for caveolin-1.  
 Cav-1 is expressed from basal layer to granular layers in verrucous carcinoma 
whereas in squamous cell carcinoma expression was from basal layer to spinous 
layer. 
 Mean value of percentage of positivity were found to be decreased from 
verrucous carcinoma (2.4) to squamous cell carcinoma(2.0) But this difference 
was not statistically significant. 
 Mean value of intensity of staining were found to be decreased from verrucous 
carcinoma (2.0) to squamous cell carcinoma(1.8) but this difference was not 
statistically significant. 
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 Mean value of immunoreactive score were found to be decreased from verrucous 
carcinoma (5.4) to squamous cell carcinoma(4.1) but this difference was not 
statistically significant. 
 In the present study, Out of 30 cases of OSCC, the IRS of Caveolin-1 expression 
was found to be negative in 2 cases; mild expression in 14 cases, moderate 
expression in 11 cases; strong expression in 3 cases. Out of 30 cases of Verrucous 
Carcinoma, the IRS of Caveolin-1 expression was found to be negative in 2 cases; 
mild expression in 10 cases, moderate expression in 10 cases; strong expression in 
8 cases. 
 
CONCLUSION 
In our study verrucous carcinoma showed increased expression when compared to 
squamous cell carcinoma indicating that when the severity of the lesion increases as from 
verrucous carcinoma to squamous cell carcinoma Cav-1 expression decreases. Probably 
cav-1 is lost during the process of ‘increase in malignant potential’ which may be due to 
oxidative stress. The significance of our findings in verrucous carcinoma cannot be 
established, as no other published study of Cav-1 expression in verrucous carcinoma is 
available. More number of studies comparing verrucous carcinoma and squamous cell 
carcinoma using Cav-1, will throw light on the role and significance of Cav-1 in oral 
carcinomas. 
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Percentage of positivity and intensity of staining of Caveolin-1 expression in 
Verrucous carcinoma 
 
 
 
 
 
S.NO PERCENTAGE OF POSITIVITY INTENSITY OF STAIN 
 FIELD 
1 
FIELD 
2 
FIELD 
3 
FIELD 
4 
FIELD 
5 
AVG FIELD 
1 
FIELD 
2 
FIELD 
3 
FIELD 
4 
FIELD 
5 
AVG 
1 2 4 3 3 3 3 3 3 3 3 3 3 
2 1 1 1 1 1 1 1 1 1 1 1 1 
3 3 2 2 2 1 2.2 3 3 3 3 3 3 
4 1 1 1 2 2 1.4 1 2 2 3 2 2 
5 3 3 2 3 0 2.2 1 1 1 1 0 0.8 
6 3 2 1 1 1 1.6 1 1 1 1 1 1 
7 1 1 1 2 2 1.4 2 1 2 1 2 1.6 
8 1 1 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 2 1 1 1 1.2 
10 2 1 2 2 1 1.6 2 2 2 3 3 2.4 
11 2 2 3 3 2 2.4 1 3 2 2 2 2.2 
12 3 3 3 3 2 2.8 2 2 2 2 1 1.8 
13 2 2 1 1 1 1.4 1 2 1 1 1 1.2 
14 3 3 3 3 2 2.8 2 2 2 3 1 2 
15 1 1 2 2 1 1.4 1 1 1 2 1 1.2 
16 1 0 1 1 0 0.6 1 0 1 1 0 0.6 
17 3 3 2 2 3 2.6 2 1 1 2 2 1.6 
18 2 1 1 2 1 1.4 2 2 1 2 2 2.2 
19 3 2 3 3 2 2.6 1 2 1 1 1 1.2 
20 3 3 3 3 3 3 3 3 3 2 3 2.8 
21 1 2 1 1 2 1.4 1 2 3 1 1 1.6 
22 3 3 3 3 3 3 3 3 3 3 3 3 
23 3 3 3 3 3 3 2 2 2 2 2 2 
24 1 2 2 3 3 2.2 1 1 1 2 2 1.4 
25 1 1 3 3 3 2.2 1 1 2 2 2 1.6 
26 2 3 2 2 0 1.8 1 1 1 1 0 0.8 
27 3 3 3 2 3 2.8 2 2 3 3 2 2.4 
28 4 3 3 3 4 3.4 3 2 2 2 3 2.4 
29 4 4 4 4 4 4 1 2 1 1 1 1.2 
30 3 2 2 1 2 2 3 2 2 2 2 2.2 
Percentage of positivity and intensity of staining of Caveolin-1expression in 
OSCC 
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4 1 1 1 2 2 1.4 1 2 2 3 2 2 
5 3 3 2 3 0 3 1 1 1 1 0 1 
6 3 2 1 1 1 1.6 1 1 1 1 1 1 
7 1 1 1 2 2 1.4 2 1 2 1 2 1.6 
8 1 1 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 2 1 1 1 1.2 
10 2 1 2 2 1 1.6 2 2 2 3 3 2.4 
11 2 2 3 3 2 2.4 1 3 2 2 2 2 
12 3 3 3 3 2 2.8 2 2 2 2 1 1.8 
13 2 2 1 1 1 1.4 1 2 1 1 1 1.2 
14 3 3 3 3 2 2.8 2 2 2 3 1 2 
15 1 1 2 2 1 1.4 1 1 1 2 1 1.6 
16 1 1 1 1 1 1 3 3 2 2 3 2.6 
17 3 3 2 2 3 2.6 2 1 1 2 2 1.6 
18 2 1 1 2 1 1.4 2 2 1 2 2 1.8 
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24 1 2 2 3 3 2.2 1 1 1 2 2 1.4 
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27 3 3 3 2 3 2.8 2 2 3 3 2 2.4 
28 1 1 1 1 1 1 3 3 3 3 3 3 
29 3 3 3 2 3 2.8 1 1 1 1 1 1 
30 3 2 2 1 2 2 3 2 2 2 2 2.2 
 
 
 
 
 
 
 
 
Percentage of positivity, intensity of staining and IRS of Caveolin-1  
expression in Verrucous carcinoma 
 
 
S.NO 
PERCENTAGE OF 
POSITIVITY 
INTENSITY OF 
STAINING 
IRS - VERRUCOUS 
1 2.6 1.8 5 
2 1.2 2 3 
3 1.2 3 4 
4 2.4 2.2 6 
5 1.2 1 2 
6 2.8 2.6 8 
7 3 1 3 
8 4 2 8 
9 1.6 1 2 
10 1.4 1.4 2 
11 1 1 1 
12 3.8 3 12 
13 3 2.8 9 
14 1.6 1 2 
15 1.4 3 5 
16 0.6 0.6 1 
17 4 2.2 9 
18 1 3.2 4 
19 1.8 2 4 
20 2.4 1.2 3 
21 4 3 12 
22 4 2.6 11 
23 3.8 3 12 
24 3 2.8 9 
25 3 1.2 4 
26 1.8 0.8 2 
27 1 1.4 2 
28 3.4 2.4 9 
29 4 1.2 5 
30 1.8 1 2 
 
 
 
 
 
 
 Percentage of positivity, intensity of staining and IRS of Caveolin-1  
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S.NO 
PERCENTAGE OF 
POSITIVITY 
INTENSITY OF 
STAINING 
IRS - OSCC 
1 3 3 9 
2 1 1 1 
3 2.2 3 7 
4 1.4 2 3 
5 2.2 0.8 2 
6 1.6 1 2 
7 1.4 1.6 3 
8 1 1 1 
9 1 1.2 2 
10 1.6 2.4 4 
11 2.4 2.2 6 
12 2.8 1.8 5 
13 1.4 1.2 2 
14 2.8 2 6 
15 1.4 1.2 2 
16 1 2.6 3 
17 2.6 1.6 4 
18 1.4 2.2 3 
19 2.6 1.2 3 
20 3 2.8 9 
21 1.4 1.6 2 
22 3 3 9 
23 3 2 6 
24 2.2 1.4 3 
25 2.2 1.6 4 
26 2 2 4 
27 2.8 2.4 7 
28 1 3 3 
29 2.8 1 3 
30 2 2.2 5 
 
 
 
 
